When a Tumor Makes a Quantum Leap: Finding Our Way Through the Fog

A Diagnosis That Upended Everything

Early in 2022, a well-to-do woman in mid-life walked into clinic with what appeared to be a garden-variety grade 1 endometrioid endometrial cancer. On paper that’s usually a “good” cancer—slow growing, hormone-sensitive, highly curable. In real life it became a stress-test of science, faith, and everyone’s patience.

Her medical chart read like an allergic manifesto:

• Antibiotics → fiery rash

• Antihistamines (oh, the irony) → numb hands, droopy eyelids

• Sleeping pills → more rash

• Painkillers → full-body itch and hives

• Antiviral for COVID-19 → pimply rash over arms and trunk

When every second-line drug turns you into a strawberry, treatment gets creative fast.

Surgery & the First Plot Twist

Gynecologic oncologist Dr. Chi-Feng Hung removed her uterus and lymph nodes. Pathology came back with a shocker: stage IIIC1—two tiny metastatic seeds (2.6 mm max) hiding in the left pelvic nodes. Strangely, the uterine tumor itself behaved politely:

• Single 4.8 × 3.7 cm mass

• Invaded < 50 % of the myometrium

• No lymph-vascular or perineural invasion

• Clear surgical margins

Yet the lymph nodes showed a serous-like flavor quite different from the original endometrioid cells. Quantum tunneling, anyone?

Microscope Wars

• ER / PR: 90 % positive—textbook hormone-friendly.

• p53: wild-type—good news; fewer genetic brakes are broken.

• MSH-6 / PMS-2: intact—no mismatch-repair defect.

In other words, everything screamed low risk—except those rogue nodes.

Tumor Board: To Chemo or Not to Chemo?

Half the team argued, “No deep invasion, no LVSI—those nodes shouldn’t exist! Observe.”

The other half countered, “Better guilty chemotherapy than innocent recurrence.”

The guilty-verdict plan won. Late 2022 she started classic paclitaxel 175 mg/m² + carboplatin AUC 5. One cycle later she was a wreck, so dosing switched to weekly paclitaxel 60 mg/m² + carboplatin AUC 1.5. The neuropathy still wouldn’t quit. She finally said “Enough,” declined radiation, and chose close surveillance with Dr. Hung—the main voice of the no-chemo faction.

Faith, Scarves, and Small Victories

Knitting three luxurious Italian-yarn scarves became her DIY rehab for chemo-damaged nerves. She gifted them to one lucky pharmacist, turning side-effect misery into tactile grace.

Two-Year Checkpoint

Pre-op tumor markers were sky-high

• CA-125: 870.5 U/mL

• CA19-9: 2698.9 U/mL

Over the next two years they slid steadily down. Mid-2024 scans (contrast-free—she’s allergic) showed no evident disease. Follow-up now revolves around marker testing and imaging only when absolutely necessary.

What This Story Teaches

1. Biology > textbook. A “low-risk” tumor can still teleport to a lymph node.

2. Shared decisions matter. The patient weighed cure rates against quality of life and owned the call to stop treatment.

3. Faith and craft heal too. Prayer and Italian merino aren’t in NCCN guidelines, but they kept her spirit—and fingers—moving.

Curated by Pharmacist Li-Hua Fang. Originally appeared in Clinical Pharmacist Journal.